"Late-breaking science is a hallmark component of every ACC Annual Scientific Session and ACC.21 will be no different," says ACC.21 Vice Chair Douglas Drachman, MD, FACC. "We are looking forward to showcasing the latest in practice-changing clinical research and facilitating critical discussion and debate."

In addition to abstract submissions, Early Bird registration opens Wednesday, Oct. 28 for members and Thursday, Nov. 12 for nonmembers. Attendees can choose from new Gold, Silver or Bronze registration packages, designed to meet a variety of individual needs.

"ACC.21 will provide a much-needed opportunity for the cardiovascular community to come together to navigate emerging science, learn from expert faculty and each other, and more importantly reengage and reconnect with colleagues from around the globe," says ACC Annual Scientific Session Chair Pamela B. Morris, MD, FACC.

Morris adds that attendees can have confidence that ACC.21 is being planned based on the latest CDC guidelines to ensure a healthy and safe environment including the required use of masks, social distancing, smaller capacity meeting rooms, and additional spacing throughout the Georgia World Congress Center. For those unable to join live in Atlanta, ACC.21 Virtual will provide an innovative digital platform for learning, collaboration and networking at times that work best for individual schedules.

"While the past six months have brought with them profound change for clinicians and patients alike, the need for education, innovation and new science to help us optimize cardiovascular care and improve outcomes remains constant," says ACC President Athena Poppas, MD, FACC. "ACC.21 promises to deliver in all of these areas."

Learn more at ACCScientificSession.org.

RETURN TO TOP

"Our collaboration with the ACC will help us design clinical trials and care pathways for some of the more challenging heart diseases and accelerate the adoption of point-of-care ultrasound by cardiovascular clinicians," says John Martin, MD, Butterfly Network's Chief Medical Officer.

"One of the key targets is heart failure, with a goal to radically change monitoring. If patients can assess their status at home via AI-guided lung scans with their clinician or care team remotely, we can avoid unnecessary and costly hospital visits. This will also provide patients with more timely intervention, improve quality of care, and improve their quality of life."

Butterfly Network has long recognized that the key to unlocking the value of ultrasound is to remove the barriers of cost and complexity in traditional systems through innovation. ACC's strategic investment in Butterfly Network and collaboration on clinical trials will increase access to point-of-care ultrasound in the management of critical cardiovascular diseases.

"Through innovative collaborations like this – directly linking the technology and clinical worlds – the ACC aims to transform cardiovascular care and improve health outcomes," says John S. Rumsfeld, MD, PhD, FACC, ACC's Chief Science and Chief Innovation Officer.

"The ACC will work in sync with Butterfly to help guide the scientific evaluation and clinical integration of point-of-care ultrasound in the management of cardiovascular conditions."

RETURN TO TOP